| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039553A1 Benzothiazole compounds |
| 04/02/2009 | WO2009023269A3 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
| 04/02/2009 | WO2008142483A3 Vaccine compositions and methods of use thereof |
| 04/02/2009 | WO2008140653A3 Humaneered anti-factor b antibody |
| 04/02/2009 | US20090088409 Serum biomarkers for early detection of acute cellular rejection |
| 04/02/2009 | US20090088408 Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics |
| 04/02/2009 | US20090088385 immunoglobulins; fibronectins; drug screening |
| 04/02/2009 | US20090088384 Therapeutic Fibrin-Derived Peptides And Uses Thereof |
| 04/02/2009 | US20090088383 Gh secretagogues and uses thereof |
| 04/02/2009 | US20090088373 Use of compositions to enhance innate immune response |
| 04/02/2009 | US20090087482 Temperature-Sensitive Liposomal Formulation |
| 04/02/2009 | US20090087449 Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus |
| 04/02/2009 | US20090087429 IL-17 homologous polypeptides and therapeutic uses thereof |
| 04/02/2009 | US20090087426 Methods for Treatment of Allergic Asthma |
| 04/02/2009 | US20090087416 novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, vectors containing the nucleic acid molecules, and cells containing the vectors |
| 04/02/2009 | US20090087414 Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
| 04/02/2009 | US20090087409 Viral Polymerase Inhibitors |
| 04/02/2009 | US20090087405 Use of Lck inhibitors for treatment of immunologic diseases |
| 04/02/2009 | US20090087389 Dehydroepiandrosterone sulfate dihydrate inhalation compositions and methods |
| 04/02/2009 | DE102007045476A1 Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 New heteroaryl acetone derivatives useful for inhibiting phospholipase A2 |
| 04/02/2009 | CA2700892A1 Reagents for inducing an immune response |
| 04/02/2009 | CA2700670A1 Prevention of allergy at weaning |
| 04/02/2009 | CA2700394A1 Modified antibody constant region |
| 04/02/2009 | CA2700295A1 Polo-like kinase inhibitors |
| 04/02/2009 | CA2699607A1 Polo-like kinase inhibitors |
| 04/02/2009 | CA2699244A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | CA2699241A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699177A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699170A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699154A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699153A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699100A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699077A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699073A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699069A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699068A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699065A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699055A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699054A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699052A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699049A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699047A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699039A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | CA2699035A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | CA2699000A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-arg-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | CA2698775A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698772A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698768A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698764A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698762A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | CA2698751A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698673A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698672A1 Use of a peptide as a therapeutic agent |
| 04/01/2009 | EP2042596A1 Polypeptides involved in immune response |
| 04/01/2009 | EP2042520A1 Method for production of limulus-positive glycolipid, limulus-positive glycolipid, and limulus-positive glycolipid blend |
| 04/01/2009 | EP2042518A2 Dual specificity antibodies and methods of making and using |
| 04/01/2009 | EP2042513A1 Galectin 9-polymer conjugate |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042503A1 Compound having acidic group which may be protected, and use thereof |
| 04/01/2009 | EP2042499A1 Salt of morpholine compound |
| 04/01/2009 | EP2042196A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 04/01/2009 | EP2042192A2 Tolerogenic fragments of natural allergens |
| 04/01/2009 | EP2042171A1 Therapeutic or prophylactic agent for allergic dermatitis |